**China’s CAR-T Therapy Approved for New Indication: Bringing New Hope to Relapsed Mantle Cell Lymphoma Patients**

**China’s CAR-T Therapy Approved for New Indication: Bringing New Hope to Relapsed Mantle Cell Lymphoma Patients**

MCL

The approval of Relmacabtagene Autoleucel brings renewed hope for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL). MCL is a rare and aggressive subtype of non-Hodgkin lymphoma (NHL). Despite advancements in treatment options over recent years, patients with R/R MCL continue to face high relapse rates and poor prognoses. Therefore, there is an urgent need for more effective and innovative therapies to improve treatment outcomes and survival expectations for these patients.

Relmacabtagene, a CD19-targeted autologous CAR-T cell therapy, works by precisely targeting and attacking cancerous B cells. It has shown remarkable efficacy in clinical studies. On August 27, 2024, the National Medical Products Administration (NMPA) officially approved the new indication for Relmacabtagene, allowing its use in adult patients with relapsed or refractory mantle cell lymphoma who have undergone at least two prior systemic therapies, including Bruton tyrosine kinase inhibitors (BTKi). This approval marks another significant milestone following Relmacabtagene’s previous approvals for R/R large B-cell lymphoma (LBCL) and follicular lymphoma (FL).

The treatment of R/R MCL has always been challenging. Traditional therapies often yield limited long-term results, particularly for patients who have failed BTKi treatment, leaving them with fewer options. The emergence of Relmacabtagene offers a new treatment avenue for these patients. Clinical studies demonstrate that this CAR-T cell therapy can significantly extend progression-free survival (PFS) and overall survival (OS), with a favorable safety profile.

The approval of this new indication not only expands the use of Relmacabtagene in treating R/R MCL but also paves the way for future advancements in MCL treatment. The application of CAR-T cell therapy, especially in high-risk patients, has shown potential in overcoming aggressive lymphomas. For patients with complex genetic characteristics and challenging treatment profiles, Relmacabtagene is undoubtedly a powerful therapeutic option.

Looking ahead, Relmacabtagene is expected to benefit more R/R MCL patients in clinical practice, pushing the boundaries of treatment in this field. As research deepens and new therapies continue to emerge, Relmacabtagene is poised to play an increasingly important role in improving patient outcomes and extending survival, offering new hope to R/R MCL patients worldwide.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in Chinafor preliminary evaluation!

WhatsApp: +86137 1795 9070

(Http://wa.me/+8613717959070)

Email: doctor.huang@globecancer.com